The impact of hypoxia and glycolysis on liver fibrosis - PubMed
2 days ago
- #liver fibrosis
- #hypoxia
- #glycolysis
- Hypoxia, glycolysis, and lactylation are key in liver fibrosis (LF), but hypoxia-, glycolysis-, and lactylation-related genes (HGLRGs) roles are unclear.
- Seven HGLRGs (CHST4, FABP5, GPC3, SOX9, SRPX, IFI16, ISG20) are upregulated in LF and show strong diagnostic value.
- FABP5 and ISG20 are elevated in activated stellate cells and human cirrhotic livers, indicating promise as biomarkers/therapeutic targets.
- These genes modulate metabolic pathways and immune-mediated fibrotic responses, with ISG20 and SOX9 linked to NK cell and M2 macrophage infiltration.
- Seven FDA-approved drugs (e.g., aspirin, tamoxifen) are identified as potential HGLRG-targeting agents for drug repurposing.
- HGLRGs contribute to LF progression through metabolic dysregulation and immune remodeling, offering strategies for improved clinical management.